83 results about "Chemokine" patented technology

The invention provides hydrogel, a porous titanium / hydrogel composite implant material and a preparation method of the porous titanium / hydrogel composite implant material. The hydrogel is obtained by photo-crosslinking and curing a hydrogel precursor solution containing acrylated beta-cyclodextrin, acrylated alendronate sodium, gelatin and a chemotactic factor. The hydrogel has a porous network structure, high elastic modulus, high fatigue resistance and excellent biocompatibility, and also has the capability of recruiting bone marrow mesenchymal stem cells (BMSCs) and the capability of promoting osteogenic differentiation of the BMSCs; the porous titanium / hydrogel composite implant material prepared from the hydrogel can effectively promote the growth of new bone tissues, has excellent osseointegration capability, obviously improves the osteogenesis repair effect and the osseointegration effect, provides a new treatment approach for the repair treatment of segmental bone defects, and has important medical significance.

Embodiments of the disclosure include methods and compositions for the treatment of splenomegaly. In specific embodiments, fibroblasts and / or fibroblast-derived materials, are utilized in at least some cases to affect the immune response of the individual in order to reduce the pathogenic levels of immune cells or cytokines and / or chemokines excreted by those immune cells.

The present disclosure provides methods of treating an immune-mediated disease in a subject in need thereof. The present disclosure provides methods of treating atopic dermatitis in a subject in need thereof. The present disclosure provides methods of treating moderate to severe atopic dermatitis in a subject in need thereof. The present disclosure provides a method of treating atopic dermatitis (AD) in a subject in need thereof, the method comprises selecting a subject suffering from AD and having an elevated level relative to a control of at least one biomarker selected from the group consisting of thymus activation regulatory chemokine (TARC), interleukin-5 (IL-5), eosinophilic granulocyte count, and lactic dehydrogenase (LDH).

The present disclosure generally relates to a viral vector carrying a synthetic cancer antigen and a chemokine. Also provided herein are compositions and uses of the viral vector for delivering, such as tagging, a tumor with the synthetic cancer antigen.

The application discloses application of DUSP4 in preparation of a marker for predicting the curative effect of immunotherapy of hepatocellular carcinoma and a sensitizing drug, and belongs to the technical field of biological medicine.The application finds that high expression of dual specificity phosphatase 4 (DUSP4) is significantly related to high response rate and long survival period of an immunological checkpoint blocking therapy for a hepatocellular carcinoma patient.DUSP4 promotes CD8+ T cell and NK cell infiltration and remodels an immune microenvironment by inhibiting a TGF-beta signal path, down-regulating an immunosuppressive factor and up-regulating an antigen presenting molecule and a chemotactic factor.The application provides a kit and a method for detecting the expression level of DUSP4 to predict an immunotherapy response, and a combined drug composition comprising a DUSP4 activator or a TGF-beta inhibitor and an immunological checkpoint inhibitor.Experiments prove that up-regulation of the expression of DUSP4 can significantly enhance T cell killing function, and produces a synergistic anti-tumor effect with an anti-PD-1 antibody.The application provides a new strategy for precise stratified treatment and overcoming immunological drug resistance of hepatocellular carcinoma.

The invention belongs to the technical field of biology, and particularly relates to application of a herba artemisiae scopariae aqueous extract in enhancing liver chemotaxis of adipose-derived mesenchymal stem cells. In order to provide a way for enhancing the liver chemotaxis of the adipose-derived stem cells, the capillary artemisia aqueous extract is used for improving the expression level of chemotactic factors of the adipose-derived stem cells in vitro and intervening the proliferation, migration and chemotaxis capabilities of the adipose-derived stem cells to liver cells, the concentration of the capillary artemisia aqueous extract is 0.5 mg / mL to 1 mg / mL, the chemotaxis time is 24 h to 48 h, and the capillary artemisia aqueous extract is used for enhancing the liver chemotaxis of the adipose-derived stem cells. And the chemotactic factors are CCR1 and CXCR4.

The invention belongs to the technical field of tumor immunity, and particularly relates to a tumor antigen and chemotactic factor co-coding system and application thereof. The invention provides a tumor antigen and chemotactic factor co-coding system. The tumor antigen and chemotactic factor co-coding system comprises a nucleotide sequence for coding a tumor antigen and a nucleotide sequence for coding a chemotactic factor. The tumor antigen and chemotactic factor co-coding system can flexibly replace an antigen sequence and chemotactic factor combination, is adaptive to different tumor types and various immunotherapy requirements, can be expanded to various solid tumor treatment scenes through a customized antigen-chemotactic factor combination in the future, and has a wide application prospect. The broad-spectrum application in tumor treatment means including tumor neoantigen vaccines, adoptive cell therapy and the like is realized.

The invention provides an application of N4BP1 in preparation of an anti-enteritis drug, relates to the technical field of biomedicine, and particularly provides an application of N4BP1 as an inhibition target in preparation of an anti-enteritis drug. Researches show that the deletion of N4BP1 can alleviate colon pathological changes and weight loss caused by DSS, increase the survival days of mice, and reduce the generation of inflammatory factors and chemotactic factors. In addition, DSS can cause increase of N4BP1 expression in mice. Therefore, occurrence and development of enteritis can be inhibited by knocking out the N4BP1, the N4BP1 inhibitor or the N4BP1 neutralizing antibody, namely, the N4BP1 can become a new target spot for treating enteritis. Meanwhile, the expression of the N4BP1 can also be used as a new index for enteritis detection.

The invention relates to methods of treating a tumor in a subject by administering to the subject the following active agents: (a) interleukin- 12 (IL-12), a nucleotide expressing IL-12, or combinations thereof; and (b) c-c motif chemokine ligand 3 (CCL3), a nucleotide expressing CCL3, or combinations thereof. The invention also relates to therapeutic compositions that include the following active agents; (a) IL-12, a nucleotide expressing IL-12, or combinations thereof; and (b) CCL3, a nucleotide expressing CCL3, or combinations thereof.

The application discloses a use of ubiquitination as a marker of systemic juvenile idiopathic arthritis, and relates to the technical field of biomedicine. The marker provided by the application is a gene combination of at least two genes in ubiquitination which participates in the occurrence of sJIA inflammation by mediating NLRs pathway; the ubiquitination includes HP, S100A9, S100A12, S100A8, IL6, CFH and UBE2D1; and the gene combination at least includes a combination of any one of HP and IL6 and UBE2D1. The application constructs a joint detection scheme of UBE2D1 and inflammatory factors, chemotactic factors or immune-related molecules, and can make up for the problems of insufficient stability or limited specificity of a single index to some extent, thereby improving the auxiliary diagnosis efficiency on sJIA. Meanwhile, the detection object involved in the application is clear, the detection mode is feasible, the detection can be carried out based on a blood sample, and the application has the advantages of relatively simple operation, strong clinical implementability, convenience for development into a detection kit, a detection chip or a matching detection reagent.

The present application relates to a kind of based on chemotactic factor CXCL12 mutant modification double specific fusion protein and its application as immune checkpoint molecule targeted degradation platform in tumor immunotherapy, belong to biological medicine field.The specific problem of the present application is how to effectively enhance the effect of tumor immunotherapy, especially solve the problem of immune escape phenomenon in tumor microenvironment in traditional immunotherapy.To this end, the present application proposes a new KineTAC targeted degradation platform, specifically designs a new chemotactic factor CXCL12 and target protein binding polypeptide (such as anti-PD-1 / PD-L1 monoclonal antibody, anti-LAG-3 monoclonal antibody, etc.) Fusion expression protein molecule, enhance its binding affinity with receptor CXCR4 and CXCR7, and avoid stimulating tumor cell growth proliferation.The fusion protein can target and degrade the immunosuppressive molecules on the surface of tumor cells and immune cells, thereby enhancing the immune response of immune cells and improving the anti-tumor effect.

The invention relates to the technical field of medicines, and particularly discloses an engineered drug-loaded macrophage for resisting transplant rejection. PD-L1 is overexpressed on the surface of a cell membrane of the engineered drug-loaded macrophage, and the engineered drug-loaded macrophage internally contains nanoparticles encapsulated with rapamycin. Due to the biological characteristic that the macrophages can respond to inflammation signals, the engineered drug-loaded macrophages can be efficiently recruited to rejection reaction parts by chemotactic factors of transplantation parts, and the engineered drug-loaded macrophages can penetrate a tissue barrier as an active carrier, respond to external stimulation to exocytosis and release nanoparticles encapsulated with rapamycin after reaching a target position, and can be used for preparing a drug carrier. Local precise delivery of PD-L1 and rapamycin is realized, and immunosuppression toxicity of systemic administration is reduced.

Provided are a chemokine CXCL12 fusion protein and a use thereof. The chemokine CXCL12 fusion protein comprises the chemokine CXCL12 and an antibody against a tumor-associated antigen. The chemokine CXCL12 and the antibody against the tumor-associated antigen are directly fused or fused by means of a linker. On the one hand, the provided chemokine CXCL12 fusion protein can promote T cell infiltration and improve targeting. On the other hand, T cell killing signals are highly dependent on target cells, and T cells generate immune signals to kill the target cells only upon coming into contact with the target cells under the mediation of the fusion protein, thereby reducing toxic side effects.

The invention relates to the field of medicines, in particular to application of a reagent for detecting a complement factor in preparation of a tinnitus diagnostic product, the complement factor is selected from a complement component, a complement regulatory protein or a complement related chemotactic factor, the complement component is selected from C3, C5 and / or C1q, and tinnitus is chronic tinnitus. The peripheral blood can be used as a sample, the chronic tinnitus can be accurately diagnosed, theoretical and experimental bases are provided for clinical diagnosis of the chronic tinnitus, diagnosis and intervention can be carried out in the early stage of tinnitus, and further deterioration is prevented.

The invention relates to Escherichia coli ML001, a specific bacteriophage thereof and an application of the Escherichia coli ML001 in preventing alcoholic liver diseases. The Escherichia coli strain ML001 and the specific bacteriophage thereof are preserved in China General Microbiological Culture Collection Center (CGMCC). Animal experiments prove that the bacteriophage can effectively reduce the level of glutamic-pyruvic transaminase and glutamic oxalacetic transaminase in the plasma of an alcoholic liver disease model mouse, which indicates that the bacteriophage has a definite liver protection function. The histopathologic examination further shows that after the phage is administered, the number of lipid droplets in the liver of the mouse is obviously reduced, and the liver lipid accumulation is effectively relieved. On the molecular mechanism level, the bacteriophage can down-regulate expression of fatty acid synthesis genes Srebf1 and Acly at the same time and inhibit a lipid synthesis pathway; meanwhile, the expression of a chemotactic factor Ccl6 is reduced, and the inflammatory response of the liver is relieved.

The present invention includes a method of characterizing disease activity in a systemic lupus erythematosus patient (SEE), comprising: obtaining a dataset associated with a blood, serum, plasma or urine sample from the patient, wherein the dataset comprises data representing the level of one or more biomarkers in the blood, serum, plasma or urine sample from each of (b) to (g); at least one innate serum or plasma mediator biomarker; at least one adaptive serum or plasma mediator; at least one chemokine / adhesion molecule biomarker; at least one soluble TNF superfamily biomarker; the inflammatory mediator biomarker SCF; at least one SLE-associated autoantibody specificity biomarker; and calculating a Lupus Disease Activity Immune.

The invention relates to a traditional Chinese medicine composition for treating ischemic heart failure and a preparation method thereof, and belongs to the field of traditional Chinese medicine pharmacy, and the traditional Chinese medicine composition is prepared from the following raw material medicines in parts by weight: 5-15 parts of cassia twig, 5-15 parts of bighead atractylodes rhizome, 5-15 parts of poria cocos, 6-12 parts of rhizoma zingiberis, 5-15 parts of acanthopanax, 10-30 parts of fructus polygoni orientalis, 3-9 parts of verbena, 6-12 parts of dogwood and 3-9 parts of honey-fried licorice root. The composition can remarkably reduce the level of N-terminal proB-type natriuretic peptide, remarkably improve pathological changes of heart tissues of model rats, regulate and control the heart functions of the model rats, improve the systolic function of the heart, relieve expression of inflammatory factors such as interleukin-1beta, interleukin-6 and tumor necrosis factor-alpha of the rats and improve the anti-inflammatory effect of the rats. The action mechanism of the compound relates to a plurality of pathways such as extracellular matrix receptor interaction, a chemotactic factor signal pathway, a relaxin signal pathway, a cyclic adenosine monophosphate signal pathway, a nuclear factor-kB signal pathway, fatty acid metabolism and a Toll-like receptor signal pathway, and the compound is an effective medicament for treating ischemic heart failure.

To provide a fusion protein capable of selectively activating its ligand moiety such as a cytokine or chemokine in a target tissue.SOLUTION: Fusion proteins are provided comprising a ligand moiety connected via a peptide linker to a ligand binding moiety which binds to the ligand moiety, such as a cytokine or chemokine, but which is capable of releasing the ligand moiety in the presence of a protease. Also provided are methods for their production, their use and pharmaceutical compositions containing such fusion proteins. It also relates to improved variants of such fusion proteins. In addition, the in vitro activity of the variants was evaluated for several cytokines.SELECTED DRAWING: Figure 1A

The invention relates to the field of biological medicine, in particular to application of IL-24 recombinant protein to preparation of medicine for treating allergic rhinitis. By utilizing the IL-24 recombinant protein, the level of local 2-type inflammation of the nasal mucosa can be reduced, expression of inflammatory factors such as IL-4, IL-5 and IL-13 and chemotactic factors such as CCL24 and CCL26 can be reduced, local inflammatory cell infiltration of the nasal mucosa can be relieved, and symptoms such as sneezing and nose catching of patients can be relieved. Meanwhile, a new treatment choice is provided for patients who are invalid in hormone resistance or desensitization treatment.

An object according to certain aspect(s) of the present invention is to provide an immunocompetent cell that expresses regulatory factors of immunocompetent cell immune function and possesses all of proliferative potential, viability, and the ability to accumulate a T cell, and an expression vector of regulatory factors of immune function for generating the immunocompetent cell. An immunocompetent cell expressing a cell surface molecule specifically recognizing a cancer antigen, interleukin 7 (IL-7), and CCL19 is generated. Preferably, the cell surface molecule specifically recognizing a cancer antigen is T cell receptor specifically recognizing the cancer antigen, and the immunocompetent cell is a T cell. Another object according to certain aspect(s) of the present invention is to provide an immunocompetent cell targeting mesothelin. An immunocompetent cell that expresses a cell surface molecule specifically recognizing human mesothelin, interleukin 7 (IL-7), and chemokine (C-C motif) ligand 19 (CCL19) is produced. It is preferred that: the cell surface molecule specifically recognizing human mesothelin should be chimeric antigen receptor (CAR) having single chain antibody, a transmembrane region, and a signaling region that induces the activation of the immunocompetent cell; and the heavy chain variable region and the light chain variable region should be connected via a peptide linker consisting of a 2- to 30-amino acid sequence.

The invention provides an NK cell, a chimeric antigen receptor and a pharmaceutical composition and application of the chimeric antigen receptor, the NK cell expresses the chimeric antigen receptor, and the chimeric antigen receptor fusion protein comprises a targeted TROP2 single-chain antibody, a transmembrane structural domain, a co-stimulation structural domain, an activation structural domain, IL-15 protein and a CXCR2 chemotactic factor from the N terminal to the C terminal. In the invention, overexpression of CXCR2 can improve the killing efficiency of CAR NK, and the killing efficiency can be improved only by combining the membrane-combined IL15 with CXCR2 in the two forms of IL15.

The present disclosure relates to a composition for promoting the activation of bone marrow-derived stem cells, including C-C motif chemokine ligand 5 (CCL5), wherein, when CCL5 is administered together with growth-related oncogene beta (GROβ) and AMD3100, it not only increases the migration of hematopoietic stem cells from bone marrow to peripheral blood, but also enhances the engraftment efficiency when the hematopoietic stem cells are transplanted into recipients.

The invention discloses a preparation method of exosome-loaded enzyme response type sandwich bionic artificial skin and application of the exosome-loaded enzyme response type sandwich bionic artificial skin in diabetic wounds. According to the prepared enzyme response type bionic artificial skin, hypoxia exosomes prepared from hypoxia stimulated cells are loaded through a fiber membrane; the engineering exosome of the high-load chemotactic factor CCL-2 is prepared by self-assembled polypeptide gel loading and inflammatory factor stimulation, and the two exosomes are combined to regulate and control the immune microenvironment of the diabetic wound surface so as to better promote the healing of the diabetic wound surface.

This invention relates to bifunctional compounds and the use of such bifunctional compounds to reduce plasma levels of extracellular target molecules via lysosomal degradation. These bifunctional compounds have cell surface receptor ligands covalently linked to ligands capable of binding to extracellular target molecules (such as growth factors, cytokines, chemokines, hormones, neurotransmitters, capsids, soluble receptors, extracellular secretory proteins, antibodies, lipoproteins, exosomes, viruses, cell or plasma membrane proteins), wherein said cell surface receptors are associated with receptor-mediated endocytosis, including lysosomal degradation mediated by desialylate glycoprotein receptor (ASGPR) and lysosomal degradation mediated by mannose-6-phosphate receptor (M6PR). Pharmaceutical compositions comprising such bifunctional compounds and methods of treating diseases or disorders mediated by extracellular molecules using such bifunctional compounds are also provided herein.

The invention belongs to the technical field of medicines, and discloses application of IRE1alpha protein or a coding gene thereof as a new target spot for treating hepatitis B virus. The invention reveals for the first time that IRE1alpha protein weakens the recruitment and function of HBV specific CD8 + T cells by promoting macrophages to be polarized to anti-inflammatory phenotypes and inhibiting secretion of chemotactic factors CCL5, and the IRE1alpha protein is a key host factor for maintaining immune tolerance. On the basis, the invention provides an application of a small-molecule inhibitor targeting IRE1alpha in resisting HBV, and provides a new molecular mechanism and a candidate drug for functional healing of HBV.

Synthetic polymer networks have been introduced into mammalian cells, rendering them incapable of dividing while retaining cellular activity. A variety of mammalian cell types, useful for example in tissue regeneration and reducing inflammation in mammals, have been generated by the inventors and found to produce a number of desirable growth factors, chemokines, cytokines and other factors, indicating uses in therapy for mammals in need of these factors.

The present invention provides novel kinocidin peptides comprising a C-terminal portion of a kinocidin, wherein the C-terminal portion encompasses an α-helical secondary structure and further displays antimicrobial activity. The kinocidin peptides of the invention are derived from and correspond to a C-terminal portion of a kinocidin that includes a γκO core and that can be a CXC, CC, or C class chemokine. Structural, physicochemical and functional properties of this novel class of antimicrobial peptides and amino acid sequences of particular kinocidin peptides are also disclosed. The invention also provides related antimicrobial methods.

The invention relates to the technical field of tumor treatment, in particular to gel for inducing formation of subcutaneous three-level lymph nodes and application of the gel in tumor treatment. The invention provides a gel for inducing formation of subcutaneous three-level lymph nodes, which is characterized in that a chemotactic factor CCL21 is wrapped in the gel, the surface of the gel is modified with an activated peptide derived from CD40L, the CCL21 can induce immigration of initial T cells and B cells of peripheral blood into the gel and meanwhile induce immigration of antigen presenting cells carrying antigens in tumors, and the formation of the subcutaneous three-level lymph nodes is induced. Therefore, it is ensured that the TLS formed under the skin is tumor-specific. Under the activation action of CD40Lp, various immune cells interact to form T zone and B zone, and finally tumor-specific immune cells are generated to promote anti-tumor immune response.

The invention discloses a sustained-release drug-loaded microsphere and a preparation method and application thereof, the sustained-release drug-loaded alginate microsphere prepared by a freeze spray drying method has good dispersibility and stability in an aqueous solution, and can effectively release loaded active components. After being injected into a tumor in situ, the hyaluronidase and the chemotactic factor can be released in a long-acting manner, the number and functions of the infiltrating T cells in the tumor are increased, the anti-tumor effect of the infiltrating T cells is effectively improved, and the T cell depletion is improved. Therefore, the time and the cost of lymphocyte in-vitro culture are shortened, and the curative effect of the tumor infiltration lymphocyte therapy is enhanced. After T lymphocytes are transfused back, sustained-release drug-loaded microspheres are injected in situ, so that the collection efficiency of the T cells at a tumor part and the activity of the T cells can be improved, the transfused T cells can play an anti-tumor role, and the curative effect is enhanced.